A nurse displays a vial of Bharat Biotech Ltd. Covaxin vaccine arranged at a Covid-19 vaccination center at a municipal hospital in Pune, Maharashtra, India, on Wednesday, May 5, 2021. Serum Institute of India Ltd., the worlds largest vaccine maker based in Pune, will deliver 220 million doses to India’s vaccine-starved federal and state governments over the next few months, which can cover 8% of the country's population. Photographer: Dhiraj Singh/Bloomberg | Photo Credit: DHIRAJ SINGH
Bharat Biotech is likely to commence pediatric trials of Covaxin from June 1, according Raches Ella, Head-Business Development & International Advocacy of the company.
He was speaking in a virtual interaction with the members of Ficci Ladies Organisation (FLO) on Saturday. The company hopes to get approval for use of the vaccine on the children after the successful completion of the trials in the third quarter of this year.
Hyderabad-based Bharat Biotech had recently received approval from the Drug Controller General of India to carry out clinical trials of Covaxin in the age group of 2 to 18 years. The trials will be conducted on 525 volunteers in select locations.
On the approval for Covaxin from the World Health Organization, Ella said the process has been initiated by the company and the approval was expected soon.
Stating that the company will be ramping up its manufacturing capacity by this year-end, he said the government had placed an advance order for vaccines worth ₹1,500 crore.
Published on May 22, 2021
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.